Rubis H1 2026 Net Income Group Share Rises 17% to €191 Million
Bitget2026/11/06 13:55- Rubis’ H1 2026 net income attributable to shareholders rose 17% year over year to €191 million.
- Energy distribution volumes climbed 9% to 3,476,000 cubic meters.
- Photosol’s operating capacity increased 32% to 799 MWp following full commissioning of the Creil solar plant.
- The group raised its 2026 EBITDA guidance to €775–825 million from €740–790 million following strong first-half performance.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.
NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.
CleanSpark presents fully funded Sandersville project in investor presentation
Forge Nano completes acquisition of HzO
Crypto prices
More
